Jim Kramer agrees to acquire Merck

We have recently published 14 stocks. Jim Kramer discussed the price of bitcoin record. Verona Pharma Plc (Nasdaq: VRNA) is one of the shares that Jim Cramer recently discussed.

Verona Pharma Plc (Nasdaq: VRNA) is a small biotechnology company that focuses on respiratory diseases. Its shares increased by 20.6 % in July after Pharma Giant Merck announced that it will buy the company at $ 10 billion. However, even before the acquisition, Verona Pharma PLC (NASDAQ: VRNA) increased by 80 %. The stock has been assisted by improving revenues and shrinking losses, which are good performance indicators for biotechnology and pharmaceutical companies. Cramer comments on Verona Pharma Plc (Nasdaq: VRNA) covered Merck:

“Yes, I spoke to Rob this morning, I really liked this.

Patient in a clinic, takes a dose of porridge to treat respiratory disease.

Earlier, the CNBC host had been called Verona Pharma Plc (Nasdaq: VRNA) as speculation:

“These arrows are a rocket ship. Once again, very speculative, because they lose a lot of money. Do you have some things that people love, but they also have a large amount of sale from the inside, frankly.”

While we acknowledge the VRNA capabilities as an investment, our conviction lies in the belief that some artificial intelligence shares have a greater promise to provide higher returns and limited risks. If you are looking for a very cheap inventory of artificial intelligence and is also a major beneficiary of the Trump and Bundge tariff, see our free report on The best inventory of artificial intelligence in the short term.

Read the following: 30 stocks must double in 3 years and 11 stocks of hidden artificial intelligence for purchase now.

Detection: Nothing. This article was originally published in A monkey from the inside.